Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

The value of mutational profiling of the cytocentrifugation supernatant fluid from fine-needle aspiration of pancreatic solid mass lesions.

Deftereos G, Finkelstein SD, Jackson SA, Ellsworth EM, Krishnamurti U, Liu Y, Silverman JF, Binkert CR, Ujevich BA, Mohanty A.

Mod Pathol. 2014 Apr;27(4):594-601. doi: 10.1038/modpathol.2013.147.

2.

Molecular analysis of centrifugation supernatant fluid from pancreaticobiliary duct samples can improve cancer detection.

Finkelstein SD, Bibbo M, Loren DE, Siddiqui AA, Solomides C, Kowalski TE, Ellsworth E.

Acta Cytol. 2012;56(4):439-47. doi: 10.1159/000339638.

3.

Determination of sequential mutation accumulation in pancreas and bile duct brushing cytology.

Lapkus O, Gologan O, Liu Y, Swalsky PA, Wilson MM, Finkelstein SD, Silverman JF.

Mod Pathol. 2006 Jul;19(7):907-13.

4.

The added value of using mutational profiling in addition to cytology in diagnosing aggressive pancreaticobiliary disease: review of clinical cases at a single center.

Malhotra N, Jackson SA, Freed LL, Styn MA, Sidawy MK, Haddad NG, Finkelstein SD.

BMC Gastroenterol. 2014 Aug 1;14:135. doi: 10.1186/1471-230X-14-135.

5.

Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses.

Reicher S, Boyar FZ, Albitar M, Sulcova V, Agersborg S, Nga V, Zhou Y, Li G, Venegas R, French SW, Chung DS, Stabile BE, Eysselein VE, Anguiano A.

Pancreas. 2011 Oct;40(7):1057-62. doi: 10.1097/MPA.0b013e3182200201.

PMID:
21705950
6.
7.

Endoscopic ultrasound fine needle aspirate DNA analysis to differentiate malignant and benign pancreatic masses.

Khalid A, Nodit L, Zahid M, Bauer K, Brody D, Finkelstein SD, McGrath KM.

Am J Gastroenterol. 2006 Nov;101(11):2493-500.

PMID:
17029619
8.

Mutational analysis of cytocentrifugation supernatant fluid from pancreatic solid mass lesions.

Finkelstein SD, Bibbo M, Kowalski TE, Loren DE, Siddiqui AA, Solomides C, Ellsworth E.

Diagn Cytopathol. 2014 Aug;42(8):719-25. doi: 10.1002/dc.23048.

9.

Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass.

Maluf-Filho F, Kumar A, Gerhardt R, Kubrusly M, Sakai P, Hondo F, Matuguma SE, Artifon E, Monteiro da Cunha JE, César Machado MC, Ishioka S, Forero E.

J Clin Gastroenterol. 2007 Nov-Dec;41(10):906-10.

PMID:
18090159
10.

EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection.

Chowdhuri SR, Xi L, Pham TH, Hanson J, Rodriguez-Canales J, Berman A, Rajan A, Giaccone G, Emmert-Buck M, Raffeld M, Filie AC.

Mod Pathol. 2012 Apr;25(4):548-55. doi: 10.1038/modpathol.2011.184.

11.

Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis.

Wang X, Gao J, Ren Y, Gu J, Du Y, Chen J, Jin Z, Zhan X, Li Z, Huang H, Lv S, Gong Y.

Am J Gastroenterol. 2011 Dec;106(12):2104-11. doi: 10.1038/ajg.2011.281.

PMID:
21876563
12.

The role of K-ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses: a meta-analysis of prospective studies.

Fuccio L, Hassan C, Laterza L, Correale L, Pagano N, Bocus P, Fabbri C, Maimone A, Cennamo V, Repici A, Costamagna G, Bazzoli F, Larghi A.

Gastrointest Endosc. 2013 Oct;78(4):596-608. doi: 10.1016/j.gie.2013.04.162.

PMID:
23660563
13.

Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer.

Bournet B, Selves J, Grand D, Danjoux M, Hanoun N, Cordelier P, Buscail L.

J Clin Gastroenterol. 2015 Jan;49(1):50-6. doi: 10.1097/MCG.0000000000000053.

PMID:
24798941
14.

Endoscopic ultrasound-guided fine needle aspirate microsatellite loss analysis and pancreatic endocrine tumor outcome.

Nodit L, McGrath KM, Zahid M, Jani N, Schoedel KE, Ohori NP, Carty S, Finkelstein S, Khalid A.

Clin Gastroenterol Hepatol. 2006 Dec;4(12):1474-8.

PMID:
16996803
15.
16.

Molecular diagnosis of exocrine pancreatic cancer using a percutaneous technique.

Evans DB, Frazier ML, Charnsangavej C, Katz RL, Larry L, Abbruzzese JL.

Ann Surg Oncol. 1996 May;3(3):241-6.

PMID:
8726178
17.

Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts.

Nikiforova MN, Khalid A, Fasanella KE, McGrath KM, Brand RE, Chennat JS, Slivka A, Zeh HJ, Zureikat AH, Krasinskas AM, Ohori NP, Schoedel KE, Navina S, Mantha GS, Pai RK, Singhi AD.

Mod Pathol. 2013 Nov;26(11):1478-87. doi: 10.1038/modpathol.2013.91.

18.

Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts.

Singhi AD, Nikiforova MN, Fasanella KE, McGrath KM, Pai RK, Ohori NP, Bartholow TL, Brand RE, Chennat JS, Lu X, Papachristou GI, Slivka A, Zeh HJ, Zureikat AH, Lee KK, Tsung A, Mantha GS, Khalid A.

Clin Cancer Res. 2014 Aug 15;20(16):4381-9. doi: 10.1158/1078-0432.CCR-14-0513.

19.
20.

Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients.

Lewandowska MA, Jóźwicki W, Jochymski C, Kowalewski J.

Oncol Rep. 2013 Sep;30(3):1045-52. doi: 10.3892/or.2013.2579.

Items per page

Supplemental Content

Support Center